Myriad Genetics INC Form 4 insider transactions

Myriad Genetics President and CEO Samraat S. Raha acquired 3,542 shares of common stock through the company's employee stock purchase plan.

Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of Myriad Genetics common stock via the employee stock purchase plan.

Myriad Genetics Director Rashmi Kumar reported a sale of 15,000 shares of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Daniel Skovronsky was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the company's 2026 equity incentive plan.

Director Lee Nisley Newcomer was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Director Mark Steven Davis was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Director S. Louise Phanstiel was granted 59,701 restricted stock units in Myriad Genetics, Inc.

Director Heinrich Dreismann acquired 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Director Colleen F. Reitan was granted 59,701 restricted stock units by Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Director Paul Bisaro was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Director Rashmi Kumar was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Myriad Genetics Chief Technology Officer, Jampa Raj, received a grant of 251,889 restricted stock units.

Director Paul Bisaro purchased 7,500 shares of Myriad Genetics common stock at an average price of $3.685 per share.

Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics Inc., reported a transaction involving the withholding of common stock to cover tax obligations.

Myriad Genetics Chief Operating Officer Mark Verratti had 1,069 shares withheld to satisfy tax obligations upon the vesting of restricted stock units.

Chief Scientific Officer Dale Muzzey disposed of 946 shares of Myriad Genetics common stock to satisfy tax obligations.

Myriad Genetics' Chief Scientific Officer, Dale Muzzey, disposed of 2,019 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Myriad Genetics' Chief Operating Officer, Mark Verratti, disposed of 2,055 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

MYRIAD GENETICS CFO Benjamin Wheeler reported a disposition of 549 common shares to cover tax obligations from vested restricted stock units.

Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, has departed the company and reported the disposition of shares related to tax withholdings from vested restricted stock units.

Myriad Genetics' Chief People Officer, Shereen Solaiman, reported the acquisition of 173,196 restricted stock units and subsequent dispositions for tax withholding.

Myriad Genetics Chief Scientific Officer Dale Muzzey reported the vesting of restricted stock units and subsequent share disposals for tax obligations.

Myriad Genetics' Chief Legal Officer, Jennifer Lynne Fox, received a significant grant of restricted stock units and had shares withheld for tax obligations.

Myriad Genetics' Chief Commercial Officer, Brian J. Donnelly, was granted 226,804 restricted stock units, increasing his beneficial ownership to 624,338 shares.

Myriad Genetics COO Mark Verratti reported the grant of 247,423 restricted stock units and subsequent tax-related share disposals.

Myriad Genetics CFO Benjamin Richard Wheeler reported the acquisition of 206,186 restricted stock units and subsequent disposals for tax withholding.

Myriad Genetics CEO Samraat Raha reported the acquisition of 618,557 restricted stock units and subsequent tax-related dispositions.

Myriad Genetics Director S. Louise Phanstiel acquired over 100,000 shares of common stock in open market purchases, increasing her direct beneficial ownership.

Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, acquired 4,994 shares of common stock through a performance-based restricted stock unit award.

Myriad Genetics Chief Operating Officer Mark Verratti acquired 32,810 shares of common stock through the vesting of performance-based restricted stock units.